Capmatinib
Capmatinib, sold under the brand name Tabrecta, is a medication for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR, as detected by an FDA-approved test. The most common adverse reactions are peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite.
primaryTopic
Capmatinib
Capmatinib, sold under the brand name Tabrecta, is a medication for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR, as detected by an FDA-approved test. The most common adverse reactions are peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite.
has abstract
Capmatinib, sold under the bra ...... tion or MET exon 14 skipping).
@en
alternative name
Tabrecta
@en
CAS number
1029712-80-8
ChEMBL
DrugBank
FDA UNII code
TY34L4F9OZ
MedlinePlus
PubChem
Link from a Wikipage to an external page
Wikipage page ID
51,248,853
page length (characters) of wiki page
Wikipage revision ID
1,012,662,001
Link from a Wikipage to another Wikipage
ATC prefix
L01
@en
ATC suffix
EX17
@en
CAS number
ChEMBL
ChemSpiderID
25,069,712
DailyMedID
Capmatinib
@en
DrugBank
DB11791
@en
KEGG
D10696
@en
D10891
@en
legal US
Rx-only
@en
MedlinePlus
a620038
@en
pregnancy category
Not recommended
@en
PubChem
25,145,656
routes of administration
SMILES
CNCC1=CF
@en
StdInChIKey
LIOLIMKSCNQPLV-UHFFFAOYSA-N
@en
synonyms
INC280
@en
tradename
Tabrecta
@en
UNII
TY34L4F9OZ
@en
wikiPageUsesTemplate
comment
Capmatinib, sold under the bra ...... spnea, and decreased appetite.
@en
label
Capmatinib
@en